enVVeno Medical Corp (NVNO) enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
enVVeno Medical Corporation NASDAQ:NVNO Healthcare · Medical - Devices
Mkt Cap $4.01M
EV -
SI 3.5%
Net Cash/Sh -
CLOSED · Nov 17 -2.94%$5.77 CLOSED · Nov 17 Prev close $5.95 -2.94%Close $5.77 0.00% AH close $5.77 VOL 11K $ Vol $65K RVOL 0.34x
Mkt Cap $4.01M
EV -
VOL 11K sh
$ Vol $65K
RVOL 0.34×
SI 3.5%
Net Cash/Sh -
Press Release
enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
enVVeno Medical will present its investigational enVVe System at the 38th annual TCT Scientific Symposium in San Diego on November 2, 2026. CEO Rob Berman will deliver the presentation during the Innovation in Endovascular Therapies session, introducing the transcatheter venous valve to a global audience of cardiovascular specialists.
• 15d ago AI analysis › Press Release
enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study
enVVeno Medical reported a Q3 2026 net loss of $4.4 million ($6.29 per share) and ended the quarter with $18.5 million in cash and investments, with quarterly burn of roughly $3 million. The company is on track to treat the first patients in the FDA-approved TAVVE pivotal study of its enVVe venous valve before year end, starting with a 10-patient safety stage before a 220-patient randomized stage.
• 18d ago AI analysis › Press Release
enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman
enVVeno Medical released the third episode of its 'WTF with Rob Berman' video series, in which the CEO discusses the total addressable market for severe deep venous insufficiency. The episode covers patient population size and the market opportunity but contains no new financial, clinical, or regulatory data.
• 27d ago AI analysis › Press Release
enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
enVVeno Medical will present its investigational enVVe System, a first-in-class non-surgical replacement venous valve, at The VEINS 2026 Summit in Las Vegas on October 4. The company reiterated that it received FDA IDE approval earlier this year for the TAVVE pivotal trial and expects enrollment to begin in Q4 2026. Severe deep venous insufficiency affects roughly 3 million U.S.
• 1mo ago AI analysis › Press Release
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
enVVeno Medical CEO Rob Berman launched a new investor-focused video series called 'WTF Rob Berman,' framing it as straight-talk facts about the company with no corporate spin. Planned topics include the enVVe bioprosthetic venous valve system, the road to the SAVVE pivotal trial, and the company's strategy as it advances toward potential commercialization in severe deep venous insufficiency. The release is purely an investor-communications effort with no new clinical, regulatory, or financial data; roughly 3 million people in the U.S.
• 2mo ago AI analysis › Press Release
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
enVVeno Medical announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing beginning September 11, 2026. The presentation features CEO Robert Berman and provides an overview of the company and its enVVe System, along with recent corporate and clinical developments.
• 2mo ago AI analysis › Press Release
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
CEO Robert Berman presented at the Virtual Investor 'Why Now' on-demand conference, discussing the company's investment opportunity and the unmet need in Deep Venous Insufficiency treatment. Berman highlighted the enVVe system, a first-in-class bioprosthetic venous valve, and noted the company's recent FDA IDE approval for the TAVVE pivotal trial. The TAVVE trial is expected to commence in Q4 2026, enrolling approximately 230 patients across up to 40 U.S.
• 2mo ago AI analysis › Press Release
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
A peer-reviewed health economic analysis published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders found enVVeno Medical's venous valve replacement therapy to be economically dominant over standard of care treatments. The study projects average healthcare savings of more than $32,000 per patient over five years and estimates $5.9 billion in annual savings system-wide with broader adoption of the technology.
• 3mo ago AI analysis › Press Release ● Major
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
enVVeno Medical reported Q2 financial results alongside a major regulatory milestone, achieving FDA IDE approval for the pivotal TAVVE trial of its enVVe System. The company ended the quarter with $21.5 million in cash and investments, which management believes funds operations into Q3 2027, while reducing its net loss by 46% year-over-year. The pivotal study is expected to commence in the second half of 2026, targeting enrollment of approximately 230 patients across up to 40 U.S.
• 3mo ago AI analysis › Press Release
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
CEO Robert Berman participated in a Virtual Investor segment to discuss the issuance of a new U.S. patent covering the enVVe system. Berman noted that the patent expands the company's IP portfolio as it advances the first FDA-approved pivotal trial for a non-surgical replacement venous valve.
• 4mo ago AI analysis › Press Release
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
enVVeno Medical announced the issuance of U.S. Patent No. 12,575,932, covering key components of its enVVe transcatheter replacement venous valve system and associated methods for treating deep venous insufficiency. The patent protection encompasses the valve, support frame, crimping system, and delivery mechanisms, reinforcing the company's competitive position as it prepares for the TAVVE pivotal study under an FDA-approved IDE.
• 4mo ago AI analysis › Press Release
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
enVVeno Medical announced that CEO Rob Berman will present at the Webull Corporate Connect Webinar Series on June 24, 2026. The session will address the significant unmet need in Deep Venous Insufficiency and the company's recent FDA IDE approval for the enVVe System. Management intends to outline plans for the first-ever U.S.
• 4mo ago AI analysis › Press Release
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
enVVeno Medical announced that CEO Robert Berman will participate in a Virtual Investor Closing Bell webcast on June 9, 2026, at 4:00 PM ET. The session will include a discussion of the company's recently reported FDA IDE approval for its enVVe System, a non-surgical replacement venous valve.
• 5mo ago AI analysis › Press Release
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
accessnewswire.com • 6mo ago Press Release ● Major
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
enVVeno Medical ended Q1 2026 with $24.9 million in cash and investments, providing a runway into Q3 2027 to support the TAVVE pivotal study. The company achieved a landmark FDA IDE approval for the TAVVE study, the first-ever FDA approval for a pivotal study of a non-surgical replacement venous valve.
• 6mo ago AI analysis › Press Release
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
accessnewswire.com • 6mo ago